Dofetilide: a new drug to control cardiac arrhythmia.

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia. Mortality, and especially morbidity caused by AF, are major and growing health problems in the western world. AF is strongly associated with arterial hypertension, congestive heart failure, valvular heart disease, ischaemic heart disease, and with prevalence increasing with age. A variety of drugs have been used to terminate or prevent AF but, as many antiarrhythmic agents have the potential life-threatening pro-arrhythmia, safety problems remain. Dofetilide (Tikosyn, Pfizer), a new Vaughan Williams class III antiarrhythmic agent, has been developed and approved for the treatment of AF. In contrast to most antiarrhythmic agents, the development programme included two safety studies in high-risk patients. Dofetilide is effective and safe when an elaborate procedure for dosing is implemented. Along with amiodarone and betablockers, dofetilide is the only antiarrhythmic drug, which is recommended by guidelines for the treatment of AF in a wide range of patients.

• Authors: Hanne Elming, Bente Brendorp, Ole Dyg Pedersen, Lars Køber, Christian Torp-Petersen
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 4 Issue 6 Pg. 973-85 (Jun 2003) ISSN: 1465-6566 [Print] England
• PMID: 12783593 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Arrhythmia Agents
• Phenethylamines
• Sulfonamides
• dofetilide

Topics

• Anti-Arrhythmia Agents (adverse effects, pharmacokinetics, therapeutic use)
• Arrhythmias, Cardiac (drug therapy, epidemiology)
• Atrial Fibrillation (drug therapy)
• Atrial Flutter (drug therapy)
• Clinical Trials as Topic
• Humans
• Phenethylamines (adverse effects, pharmacokinetics, therapeutic use)
• Practice Guidelines as Topic
• Product Surveillance, Postmarketing
• Sulfonamides (adverse effects, pharmacokinetics, therapeutic use)
• Tachycardia, Supraventricular (drug therapy)